AUTHORS
Heather J. Landau, MD, Aaron S Rosenberg, MD2, Jeffrey A. Zonder, MD3, Raymond Comenzo, MD4, Vaishali Sanchorawala, MD5, Michaela Liedtke, MD6, Amandeep Godara, MD7, Jonathan L Kaufman, MD8, Al-Ola Abdallah, MD9, Binoy Yohannan, MD10, Larry D Anderson Jr, MD, PhD11, Naresh Bumma, MD12, Swathi Namburi, MD13, Michael Rosenzweig, MD14, Hailey Simone, BSN, RN, OCN15, June Song, RN16, Charlotte FM Hughes, MD17, Mehrdad Abedi, MD18, Jennifer Liu19, David Marks, MD20, Eugene Brailovski21, Shahzad Raza, MD22
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York City, United States
2 UC Davis Comprehensive Cancer Center, Sacramento, United States
3 Barbara Ann Karmanos Cancer Institute, Detroit, Missouri, United States
4 Tufts Medical Center, Boston, Massachusetts, United States
5 Boston Medical Center, Boston, Massachusetts, United States
6 Stanford Medicine, Stanford, California, United States
7 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
8 Emory Healthcare, Atlanta, Georgia, United States
9 University of Kansas Medical Center, Kansas City, Kansas, United States
10 University of Minnesota Medical School, Minneapolis, Minnesota, United States
11 Myeloma, Waldenstrom’s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
12 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
13 Swedish Health Services, Seattle, Washington, United States
14 City of Hope, Duarte, California, United States
15 Memorial Sloan Kettering Cancer Center, New York City, United States
16 Memorial Sloan Kettering Cancer Center, New York City, United States
17 Memorial Sloan Kettering Cancer Center, New York City, United States
18 UC Davis Comprehensive Cancer Center, Sacramento, United States
19 Memorial Sloan Kettering Cancer Center, New York City, United States
20 Nexcella, Inc., Los Angeles, California, United States
21 Memorial Sloan Kettering Cancer Center, New York City, United States
22 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
ABSTRACT
Background: No FDA approved treatments exist for relapsed/refractory (RR) AL Amyloidosis. This study reports safety and efficacy data from all 45 patients (pts) in NEXICART-2, the first U.S. clinical trial of any CAR-T in RR AL Amyloidosis.
Methods: NEXICART-2 (NCT06097832) is a single-arm, multi-site U.S. Phase 1/2 trial of sterically-optimized autologous BCMA CAR-T NXC-201 with a proprietary CD3ζ, CD8 hinge and binder designed to reduce off-target activation in RR AL Amyloidosis. Included pts were previously treated with both a proteasome inhibitor and an anti-CD-38 antibody and had persistent or relapsed disease at enrollment (difference in involved and uninvolved free light chain (dFLC) >5mg/dL, dFLC >2mg/dL with abnormal k:l ratio, or serum m-spike >0.5g/dL). Lymphodepletion was fludarabine and cyclophosphamide. The primary endpoint was complete hematologic response (CR) rate (Palladini 2012, 2020, 2021), assessed by an Independent Review Committee (IRC). Cardiac and renal responses were assessed by consensus criteria (Comenzo 2012; Palladini 2014), adjudicated by IRC.
Patient Characteristics: 45 pts (20F, 25M) with median age 65y (range: 47 - 82) were included. Median follow-up was 277d (range: 90 - 756). Median prior lines of therapy was 3 (range: 1 - 10), including 17 pts (38%) with at least 1 prior autologous stem cell transplant. Among pts in study based on dFLC, median dFLC at enrollment was 6.5 mg/dL (range: 2.2 - 31.0). Among pts in study based on m-spike, median m-spike at enrollment was 0.59 g/dL (range: 0.5 - 0.79). Median NT-proBNP was 393 ng/L (range: 36 - 6,088). Sixty-two percent of pts (28/45) had cardiac involvement. Of pts with cardiac involvement, cardiac staging was more advanced at diagnosis (Mayo stage I, II, IIIa, IIIb, no staging available n = 1, 12, 10, 1, 4, respectively) and more modest at enrollment (Mayo stage I, II, IIIa, n = 9, 12, 7, respectively). Additionally, 13/28 cardiac pts had New York Heart Association (NYHA) class II heart failure. Thirty-eight percent (17/45) of pts had kidney involvement, with median proteinuria of 2.1g/24h (range: 0 - 10.3) in these 17 pts. 19 pts had 1q21 gain (42%) and 4 (9%) had 17p deletion. Two pts (4%) had t(4;14), 3 (7%) had t(11;14), and 3 (7%) had t(14;16) translocations.
Safety: 3 pts received 150 million and 42 received 450 million CAR+T cells, with median vein-to-vein time 14 days (range: 13 - 15). Cytokine release syndrome (CRS) was observed in 38 pts (grade 1 (n = 29), grade 2 (n = 9)). Median CRS onset was on day 1 (range: 1 - 8), with median duration of 1 day (range: 1 - 5). No immune effector cell associated neurotoxicity or neurotoxicity of any kind was observed. Adverse events included neutropenia (grade 2 (n = 6), grade 3 (n = 15), grade 4 (n = 22)). One pt experienced grade 3 febrile neutropenia without an associated infection, and 2 pts with pre-existing atrial fibrillation experienced transient arrythmias controlled by beta-blockers. There were no treatment-related infections.
Efficacy: 96% of pts (43/45) normalized pathological disease markers (involved FLC or m-spike) after NXC-201 treatment. FLCs normalized at a median of 7 days (range: 7 - 27), all with reduction to <1 mg/dL. Forty-three pts (n=43/45) are in VGPR/CR, including all 17 with 1q21 gain. Of pts with >12 months (12m) follow-up, the CR rate was 100% (16/16), ongoing, including 2 pts >2 years. Of remaining pts with <12m follow-up, 96% (26/27) are MRD-negative by flow cytometry or clonoSEQ (10-5/10-6 sensitivity) (2 pts MRD status not yet available). All pts who reached MRD-negativity at D25 visit subsequently reached CR within 12m. One pt withdrew and subsequently progressed. Organ responses: 100% (9/9) of evaluable pts had a cardiac organ response at median 0.9 (range: 0.8 – 3.0) months; 100% (11/11) of evaluable pts had a renal organ response at median 2.0 (range: 0.2-10.8) months. Median reduction in NT-proBNP and proteinuria/24h at last measurement for pts with >18 months of follow-up was 57% and 91%, respectively. Median duration of complete response has not yet been reached. Updated results will be communicated at presentation time.
Conclusion: In the first reported U.S. CAR-T clinical trial of 45 pts with RR AL amyloidosis, NXC-201 safely resulted in rapid and durable complete responses, which translated into rapid organ responses. These results establish NXC-201 CAR-T as a safe and efficacious therapeutic option in a disease with no approved treatments.
DISCLOSURES
Heather J. Landau, MD: Nexcella - Honoraria; Alexion - Honoraria; Karyopharm - Honoraria; Arcellx - Honoraria; Bristol Myers Squibb - Honoraria; AbbVie - Honoraria; Pfizer - Honoraria; Protego - Research Funding; Alexion - Research Funding; AbbVie - Research Funding; Nexcella - Research Funding; Prothena - Research Funding; AbbVie - Consultancy (Includes expert testimony); Arcellx - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Alexion - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Nexcella - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony)